Principal Investigator
Mario Saporta
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220209
Clinical Trial Summary
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study toEvaluate the Pharmacodynamic EffIcacy and Clinical Benefit ofAT-007 in Patients with SoRbitol Dehydrogenase (SORD) DEficiency
Phase
Phase II/III
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Mario Saporta
Phone Number
+1 (305) 2432507
Email
mas638@miami.edu